Abeona Therapeutics (NASDAQ:ABEO) Releases Earnings Results, Beats Expectations By $0.03 EPS

Abeona Therapeutics (NASDAQ:ABEO) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03, FiscalAI reports. The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $4.57 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN launch momentum is building, with Abeona treating 5 commercial patients to date, activating 6 qualified treatment centers, and reporting $8.7 million in Q1 2026 net product revenue.
• Management said payer coverage is broadening, with published policies now covering 95% of commercially insured lives and no final payer denials or patient attrition reported so far.
• The company highlighted a deepening patient pipeline, including more than 100 identified patients across centers and the community, plus 45 active referral physicians and several biopsies scheduled this quarter.
• Abeona announced an in-licensed PSMA CAR-T asset for advanced prostate cancer, paid a $7 million upfront fee, and expects first-in-human studies to begin in the second half of 2027 after a June 2026 pre-IND meeting.
• Management said the balance sheet remains strong with $168.3 million in cash and short-term investments, and reiterated expectations for near-term profitability depending on biopsy and treatment cadence.

Abeona Therapeutics Price Performance

ABEO opened at $5.60 on Friday. The stock has a fifty day moving average of $5.08 and a 200-day moving average of $5.04. The firm has a market capitalization of $318.53 million, a P/E ratio of 5.77 and a beta of 1.35. Abeona Therapeutics has a 12-month low of $4.00 and a 12-month high of $7.54. The company has a quick ratio of 6.74, a current ratio of 6.93 and a debt-to-equity ratio of 0.05.

Insider Activity

In other news, insider Madhav Vasanthavada sold 5,548 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $5.96, for a total value of $33,066.08. Following the completion of the sale, the insider owned 313,071 shares in the company, valued at $1,865,903.16. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

Institutional Trading of Abeona Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in shares of Abeona Therapeutics during the second quarter worth $27,000. Russell Investments Group Ltd. purchased a new stake in shares of Abeona Therapeutics during the third quarter worth $37,000. Truvestments Capital LLC raised its holdings in shares of Abeona Therapeutics by 191.4% during the fourth quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 6,770 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in shares of Abeona Therapeutics during the third quarter worth $64,000. Finally, Man Group plc purchased a new stake in shares of Abeona Therapeutics during the second quarter worth $67,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABEO has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday, March 19th. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a report on Tuesday, March 17th. Finally, Oppenheimer restated an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $19.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.